A study conducted on mice showed promising results that Cleveland BioLabs Curaxin drugs could be effective in treating a type of early childhood cancer when used in conjunction with two other drugs, the Buffalo drug development company said Thursday.
The early stage clinical study found that the Cleveland Bio-Labs drug, CBL0137, was effective in treating tumors associated with an often difficult to treat type of cancer, neuroblastoma, when used in tandem with two other drugs, cyclophosphamide and topotecan. When those three drugs were administered either orally or intravenously, "complete tumor regression" occurred in all of the test animals, Cleveland BioLabs said.
The results "offer hope to physicians, patients and their families and encourage us to make further progress with this research as quickly as possible," said Michelle Haber, the executive director of Children's Cancer Institute Australia.
The results of the study were presented by Haber at a medical conference in Toronto earlier this week. The experiments were conducted by scientists at the Australian institute, as well as Roswell Park Cancer Institute, Cleveland BioLabs and the company's Incuron subsidiary, which is a Moscow-based joint venture between Cleveland BioLabs and Bioprocess Capital Ventures.
The experiments showed that treating neuroblastoma with CBL0137 and standard chemotherapy delayed tumor development and prolonged survival, but neither treatment alone was capable of causing complete tumor regression.